Prophylaxis of Clostridium difficile infection
Prophylaxis of Clostridium difficile infection
批准号:
8818098
负责人:
Ernesto V Abel-Santos
金额:
$69.22万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-01 至 2019-11-30
关键词:
AcidsAcquired Immunodeficiency SyndromeAmidesAnimal ModelAntibioticsBacteriaBenchmarkingBiological AssayCellsCholic AcidsClostridium difficileCommunicable DiseasesContractsDataDiarrheaDiseaseDrug KineticsEnvironmentExcretory functionFluoroquinolonesGerminationGoalsGrantHamstersHospitalsHumanIn VitroInfectionInfection preventionInhibitory Concentration 50IntestinesLeadLeadershipLinkMalignant NeoplasmsMammalian CellMapsMetabolismMetronidazoleModelingModificationMusPatientsPermeabilityPharmaceutical ChemistryPreventionProcessPropertyProphylactic treatmentPumpRelapseReproduction sporesResearch DesignResistanceRiskRodentSerologicalSideStructureStructure-Activity RelationshipSurfaceSymptomsTestingToxic effectToxicity TestsToxinTransplant RecipientsTreatment FailureVancomycinabsorptionanalogbasebile saltscostdesigndisorder controldrug developmentgenotoxicitygut microbiotaimprovedin vitro Assayin vitro testingin vivoinformation gatheringmortalitymouse modelpharmacophorepre-clinicalpreclinical studypreventprophylacticpublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Clostridium difficile infection (CDI) is a major identifiable cause of nosocomial antibiotic-associated diarrhea. In the US alone, there are approximately 500,000 CDI cases annually, with a mortality rate >2.5%. The annual CDI-associated costs are estimated at $3.2 billion. The infectious form of C. difficile is the spore, a
resistant structure that can survive on hospital surfaces for extended periods. C. difficile spore do not cause disease, but can revert to toxin-producing bacteria (a process called germination) in the microbiota-depleted gut of hospitalized patients. We have found a synthetic bile salt (CamSA) that inhibits C. difficile spore germination and more importantly protects mice from CDI without toxic effects. CamSA also synergizes with vancomycin to protect hamsters from CDI. Although CamSA has many attractive properties, it still needs to be optimized for pre-clinical trials. We have assembled a team with complementary expertise to help improve the pharmacological properties of CamSA. At the start of this project, we will finish optimizing the necessary assays using CamSA as our lead compound. The data acquired for CamSA will serve as benchmarks for new analogs (specific aim 1) to be tested in vitro and in vivo (specific aims 2-4). At each step, GO/NO GO criteria will eliminate sub-optimal analogs. The information gathered will be used to inform the rational design and synthesis of more potent and stable anti- germinants. This iterative process will be continued until an optimized CDI prophylactic lead is obtained. The specific aims are designed to be interdependent. CamSA has already moved through much of this process since it was easily synthesized (specific aim 1), tested in a battery of in vitro assays (specific aim 2), and tested as a CDI prophylactic in rodents (specific aim 3). Moreover, we have "primed the pump" by finding three new anti-germinants that are ready for in vitro and in vivo testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of estrus cycle stages on murine CDI severity
-
批准号:10625792
-
项目类别:
-
资助金额:$14.61万
-
财政年份:2023
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Prophylaxis of Clostridium difficile infection
-
批准号:8968227
-
项目类别:
-
资助金额:$63.91万
-
财政年份:2014
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Prophylaxis of Clostridium difficile infection
-
批准号:9187862
-
项目类别:
-
资助金额:$63.91万
-
财政年份:2014
-
负责人:Ernesto V Abel-Santos
-
依托单位:
The role of calcium-DPA in the virulence of Bacillus anthracis spores
-
批准号:8434772
-
项目类别:
-
资助金额:$39.85万
-
财政年份:2013
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:6838208
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:7214753
-
项目类别:
-
资助金额:$28.07万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:6694060
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:7327573
-
项目类别:
-
资助金额:$13.32万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:7004534
-
项目类别:
-
资助金额:$17.59万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
Antimicrobial targets of intracellular cyclic peptides
-
批准号:6558817
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2003
-
负责人:Ernesto V Abel-Santos
-
依托单位:
海外基金